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Abstract
Background: Anti-citrullinated protein antibodies (ACPA) are associated with more severe joint erosions in
rheumatoid arthritis (RA), but the underlying mechanism is unclear. Recent in vitro and murine studies indicate that
ACPAs can directly activate osteoclasts leading to bone erosions and pain. This study sought evidence for this
hypothesis in humans and evaluated whether in patients with arthralgia who are at risk of RA, ACPA is associated
with erosions (detected by magnetic resonance imaging (MRI)) independent of inflammation, and also independent
of the presence of rheumatoid factor (RF).
Methods: Patients with Clinically Suspect Arthralgia (n = 507) underwent determination of ACPA and RF and 1.5 T
contrast-enhanced MRI of the metacarpophalangeal, wrist and metatarsophalangeal joints at baseline. MRIs were
scored for presence of local inflammation and erosions. Comparisons of erosion scores were performed using the
Kruskal-Wallis test. To evaluate if inflammation is, in statistical terms, intermediary in the causal path of ACPA and
erosions, three-step mediation analysis was performed using linear regression.
Results: ACPA-positive patients had higher erosion scores than ACPA-negative patients (p = 0.006). ACPA-positive
patients without subclinical inflammation did not have higher erosion scores than ACPA-negative patients (p = 0.68), in
contrast to ACPA-positive patients with local inflammation (p < 0.001). Mediation analyses suggested that local
inflammation is in the causal path of ACPA leading to higher erosion scores. Compared to ACPA-negative/RF-negative
patients, ACPA-positive/RF-negative patients did not differ (p = 0.30), but ACPA-positive/RF-positive patients had higher
erosion scores (p = 0.006).
Conclusions: The effect of ACPA on erosions is mediated by inflammation and is not independent of RF.
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Background
Although anti-citrullinated protein antibodies (ACPA) are
the most important risk factor for joint destruction in
rheumatoid arthritis (RA), the underlying pathophysio-
logical process is unclear. Traditionally, it is hypothesized
that ACPAs can enhance inflammation [1] (for instance via
immune complexes that stimulate macrophages to secrete
pro-inflammatory cytokines) and that inflammation is
required for destruction, resulting in e.g. visible bone ero-
sions on radiographs. Recent in vitro studies and mouse
models have generated a new concept in which ACPA can
directly induce osteoclast activation, followed by autocrine
enhancement of osteoclast maturation and activation [2, 3].
This may subsequently lead to bone loss (and pain) as
observed in studies performed in vivo following injection of
ACPA [2–5]. The finding that ACPA can be present long
before synovitis is clinically detectable [6] and that sensitive
imaging techniques have detected small erosions in patients
with arthralgia [7] fit with the hypothesis that joint inflam-
mation is not necessary to generate erosions [5]. Despite
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observations made in vitro and in vivo in mice [2, 3], there
is presently little information available on ACPA-positive
patients in the absence of local inflammation. Hence, it is
not known if ACPA can lead to bone erosions only with
concurrent presence of inflammation, or that ACPA
induces direct osteoclast activation (leading to erosions
without requiring concomitant inflammation) in humans as
well. By performing association studies in patients that are
in the disease phase of arthralgia without the presence of
clinical synovitis, information on these relationships can be
obtained as only a proportion of the patients with arthralgia
display subclinical inflammation. Therefore, the arthralgia
setting provides the possibility to study associations
between ACPA, (local) inflammation and erosions.
Likewise, this setting can also be used to answer
whether the effect of ACPA - if any - is dependent on
the presence of rheumatoid factor (RF). Studies within
early (rheumatoid) arthritis, using high-resolution com-
puted tomography (CT), have shown that combined
presence of ACPA and RF is associated with the number
and size of erosions rather than ACPA alone [8]. In
addition, it has been shown that patients with early
arthritis harboring both ACPA and RF display increased
osteitis scores as detected by magnetic resonance imaging
(MRI), in contrast to ACPA single-positive patients [9].
With the aim to find supporting evidence that ACPAs
themselves are directly linked to bone erosions in
humans, this study in patients with Clinically Suspect
Arthralgia evaluated whether (1) ACPA were associated
with higher erosion scores (detected by MRI) independ-
ent of the presence of inflammation, and (2) whether
higher erosion scores were associated with ACPA alone
or with ACPA and RF combined.
Methods
Patients
Patients with arthralgia (n = 507) consecutively included in
the Leiden Clinically Suspect Arthralgia cohort between
April 2012 and September 2017 were studied. Clinically Sus-
pect Arthralgia (CSA) was defined as: recent-onset (< 1-year)
arthralgia in small joints, without clinically detectable syno-
vitis (i.e. joint swelling) on physical examination, while the
treating rheumatologists considered the patients suspicious
of progression to RA based on their clinical presentation
[10]. General practitioners in our region rarely performed
ACPA or RF testing before referral [11]; hence this
infrequently affected inclusion decisions [10]. After inclu-
sion, patients were considered ACPA positive (EliA cyclic
citrullinated peptide (anti-CCP2), Phadia, Nieuwegein, the
Netherlands) if levels ≥7 U/mL) were detected, RF positive
(as described previously, in-house ELISA [12]) if levels ≥3.
5 IU/mL were detected and C-reactive protein (CRP) posi-
tive if levels ≥5.0 mg/L were detected. The cohort has previ-
ously been described in detail [10]. Informed consent was
obtained from all subjects. The local medical ethical com-
mittee approved the study.
Within 1–2 weeks after inclusion, patients underwent
1.5 T contrast-enhanced MRI of the 2nd to 5th metacar-
pophalangeal joints (MCP2–5), wrist and the 1st to 5th
metatarsophalangeal joints (MTP1–5) of the most pain-
ful side (see Additional file 1: Methods for MRI proto-
col). Disease-modifying anti-rheumatic drugs were not
used. Non-steroidal anti-inflammatory drugs (NSAIDs)
were stopped 24 h before the patients underwent MRI.
The MR images were scored for erosions, bone marrow
edema (BME), synovitis [13] and tenosynovitis [14], by
two readers as described in Additional file 1: Methods.
Within-reader intraclass correlation coefficients (ICC)
were 0.98 and 0.99; the between-reader ICC was 0.96.
Inflammation
Inflammation was assessed in two ways: first, local
inflammation was considered present if there was MRI-
detected BME, synovitis or tenosynovitis that was more
than that observed in age-matched symptom-free
controls [15] in ≥ 1 joint (Additional file 1: Methods).
Second “any inflammation” was defined as the presence
of either local subclinical inflammation (MRI-detected
synovitis, BME or tenosynovitis) and/or elevated CRP. In
this second analysis, “any inflammation” (i.e. systemic
inflammation) was taken into consideration as it could
be argued that the presence of increased acute phase
reactants in patients that have no subclinical joint
inflammation as detected with MRI indicates that some
inflammation is present in these patients.
Analyses
Erosion scores were compared using the Kruskal-
Wallis test. To evaluate if inflammation is, in statis-
tical terms, intermediary in the causal path of ACPA
and erosions, mediation analyses were performed as
described by Baron and Kenny [16]. Here, linear
regression was used to evaluate in three steps if local
inflammation is a mediator in the causal path of
ACPA presence and erosion score as outcome. First,
the association between presence of ACPA and
erosions was investigated. Second, the association
between presence of ACPA and severity of local
inflammation was investigated. Finally, both ACPA
and local inflammation were entered into the
model and we tested whether this effect was different
from the association between ACPA alone and ero-
sion score. The percentage of mediation was calcu-
lated. All regression analyses were corrected for age.
Additionally, triple stratification was applied for
ACPA, RF and local subclinical joint inflammation.
The Statistical Package for the Social Sciences (SPSS)
version 23.0 was used.
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Results
Patients with CSA had a mean age of 44 years, 77% were
female and presence of local subclinical joint inflamma-
tion on MRI was observed in 50% of patients (n = 255):
64% of the patients included met the European League
Against Rheumatism (EULAR) definition of arthralgia
suspicious of progression to rheumatoid arthritis (3/7
items present) [17]. Further characteristics are shown in
Table 1.
ACPA with concomitant inflammation, but not ACPA
alone, associated with higher erosion scores
First a comparison was made between all ACPA-positive
patients and ACPA-negative patients: ACPA-positive
patients had higher erosion scores than ACPA-negative
patients (p = 0.006; Fig. 1a). Also the presence of MRI-
detected subclinical inflammation was associated with
higher erosion scores (p < 0.001; Fig. 1b).
Next, stratification was applied for both ACPA and local
subclinical joint inflammation. After this stratification, it
was observed that in the absence of local subclinical inflam-
mation ACPA-positive (ACPA+/MRI−) patients did not
have higher erosion scores than ACPA-negative (ACPA
−MRI−) patients (p = 0.68). In contrast, ACPA-positive pa-
tients with local inflammation (ACPA+/MRI+) did have
higher erosion scores than ACPA-negative patients without
local inflammation (ACPA−/MRI−; p < 0.001; Fig. 1c).
Furthermore, comparing ACPA-positive patients without
local inflammation (ACPA+/MRI−) to ACPA-positive
patients with local inflammation (ACPA+/MRI+) revealed
that the latter group had significantly higher erosions scores
(p = 0.016, Fig. 1c). This suggests that ACPA with concomi-
tant inflammation, but not ACPA “alone”, was associated
with higher erosion scores.
When “any inflammation” (considering inflammation
positive if either local subclinical joint inflammation
was present or CRP was elevated) was studied, strati-
fied analyses revealed similar results (Additional file 1:
Figure S1). Also here, patients that had ACPA and in-
flammation had higher erosion scores, in contrast to
patients that had ACPA without concomitant inflam-
mation (p = 0.056).
ACPA levels within ACPA-positive patients (com-
paring tertiles) were not associated with erosion
scores (Additional file 1: Figure S2).
Mediation analyses; local inflammation is in the causal
path of ACPA and erosions
We studied whether local inflammation is inter-
mediary in the causal path of ACPA and erosions in
three steps using mediation analyses. In linear re-
gression analysis (Fig. 2), the presence of ACPA was
significantly associated with erosion score (β 0.72;
95% CI 0.23–1.2; p = 0.004). Likewise, presence of
Table 1 Baseline characteristics of the patients with Clinically Suspect Arthralgia (N = 507)
Patient characteristic
Age in years, mean (SD) 44 (13)
Female sex, n (%) 390 (77)
Family history of RA, n (%) 147 (29)
Symptom duration in weeks, median (IQR) 17 (9–32)
Presence of morning stiffness ≥60 min, n (%) 182 (36)
Current smoker, n (%) 137 (27)
68-TJC, median (IQR) 6 (3–10)
Increased CRP (≥5 mg/L), n (%) 106 (21)
Presence of local subclinical joint inflammation, n (%) 255 (50)
Positive for EULAR definition for arthralgia suspicious for progression to RA [17], n (%) 325 (64)
Autoantibody status
Negative for IgM-RF and ACPA, n (%) 385 (76)
IgM-RF-positive (≥3.5 IU/mL), ACPA-negative, n (%) 52 (10)
ACPA-positive (≥7 U/mL), IgM-RF-negative, n (%) 15 (3)
IgM-RF-positive and ACPA-positive, n (%) 55 (11)
ACPA-level (U/ml) in ACPA-positive patients, median (IQR) 162 (35–340)
ACPA-level (U/ml) in ACPA-positive patients without local joint inflammation, median (IQR) 129 (23–340)
ACPA-level (U/ml) in ACPA-positive patients with local joint inflammation, median (IQR) 191 (38–340)
Local subclinical joint inflammation was identified if the prevalence of magnetic resonance imaging (MRI)-detected bone marrow edema, synovitis or
tenosynovitis was higher than that of age-matched symptom-free controls
ACPA anti-citrullinated peptide antibody, CRP C-reactive protein, EULAR European League Against Rheumatism, IgM-RF immunoglobulin M rheumatoid factor, IQR
interquartile range, RA rheumatoid arthritis, RF rheumatoid factor, SD standard deviation, TJC tender joint count
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ACPA was also significantly associated with the se-
verity of local inflammation (β 3.2; 95% CI 1.8–4.6;
p < 0.001). Importantly, presence of ACPA no longer
had a significant effect on the erosion score when
corrected for inflammation (β 0.31; 95% CI − 0.15 to
0.77; p = 0.18). Together, these results indicate that
subclinical inflammation is a mediator acting in the
causal path of ACPA leading to erosions and the
mediator could account for more than half of the
total effect: (A*B)/(A*B + C′) = 0.57.
ACPA in the presence of RF, but not ACPA alone,
associated with higher erosion scores
ACPA-positive patients with local inflammation were
more often RF-positive (81%) than ACPA-positive
patients without local inflammation (67%, p = 0.28).
Stratification was therefore applied for ACPA and RF:
studying the combinations of ACPA positivity and RF
positivity revealed that ACPA-positive/RF-negative pa-
tients had similar erosion scores as did ACPA-negative/
RF-negative patients (p = 0.30). However, patients having
Fig. 1 Histograms showing median erosion scores in patients with Clinically Suspect Arthralgia comparing anti-citrullinated protein antibodies (ACPA)-positive
and ACPA-negative patients (a), patients positive or negative for local subclinical joint inflammation (b), ACPA positivity and negativity in relation to the
concomitant presence of magnetic resonance imaging (MRI)-detected subclinical inflammation (c), or rheumatoid factor (d). Median erosion scores with the
upper limit of the interquartile range (75th percentile): **p< 0.01; *p< 0.05; NS, non-significant. The following comparisons have been made: ACPA+ vs. ACPA
− (a) (p= 0.006) and MRI+ vs. MRI− (b) (p< 0.001). Next, ACPA+MRI− vs. ACPA–MRI– patients (c) (p= 0.68), ACPA+MRI+ vs. ACPA−MRI– patients (c) (p<0.001)
and finally ACPA+MRI− vs. ACPA+MRI+ (c) (p= 0.016). ACPA+ rheumatoid factor (RF)− patients vs. ACPA−RF− patients (d) (p= 0.30) and ACPA+RF+ patients
vs. ACPA−RF− patients (d) (p= 0.006)
Fig. 2 Mediation analyses showing that inflammation is in the causal pathways of anti-citrullinated protein antibodies (ACPA). Schematic overview of the
causal paths that were studied using mediation models as described by Baron and Kenny. The diagram illustrates the two causal paths that can lead to the
outcome; a direct path from the independent to the outcome (C) and an indirect path from the mediator to the outcome (B). Finally, there is a path between
the independent variable and the mediator (A). According to the description of Baron and Kenny, to test for mediation the following three regression
analyses need to be performed [16]: (1) regress the mediator on the independent variable (A) - the independent variable should significantly affect the
mediator; (2) regress the dependent (outcome) variable on the independent variable (C) - also here the independent variable should significantly affect the
outcome; (3) regress the dependent variable on both the mediator and the independent variable (B and C′ in one model); in the case of mediation the
mediator is significantly associated with the outcome and the effect of the independent variable on the outcome is less than in step 2 (partial mediation) or
there is no effect at all (full mediation). In this study, the hypothesis was tested whether severity of local inflammation detected with magnetic resonance
imaging (MRI) acts as a mediator in the causal path of the presence of anti-citrullinated protein antibodies (ACPA) on the erosion score. The data revealed that
inflammation mediated the effect of ACPA on bone erosions. The mediator could account for more than half of the total effect: (A*B)/(A*B + C′) = 0.57
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both ACPA and RF had significantly higher erosion
scores (p = 0.006; Fig. 1d) as compared to ACPA-
negative/RF-negative patients.
Finally, triple stratification for ACPA, RF and local sub-
clinical joint inflammation was performed (Fig. 3). First, we
investigated if the single presence of ACPA or RF was asso-
ciated with higher erosion scores. As compared to the
ACPA−RF−MRI− reference group (median erosion score 1.
0), there were no differences in patients only positive for
ACPA (ACPA+RF−MRI−; median 1.0; p = 0.85), nor in pa-
tients single-positive for RF (ACPA−RF +MRI−; median 0.
5; p = 0.35) or patients positive for both ACPA and RF, but
without subclinical joint inflammation (ACPA+RF +MRI−;
median 1.0; p = 0.65). ACPA+RF +MRI− patients (median
1.0) did not have significantly higher erosion scores than
ACPA−RF +MRI− patients (median 0.5; p = 0.91). We then
investigated if erosion scores were significantly higher if
concomitant inflammation was present in addition to the
presence of ACPA and/or RF. Compared to ACPA−RF
−MRI− patients, significantly higher erosion scores were
observed in ACPA-positive patients with concurrent in-
flammation (ACPA+RF−MRI+; median 2.0; p = 0.033), and
in RF-positive patients with concomitant inflammation
(ACPA−RF +MRI+; median 2.25; p = 0.001). Finally, we
studied the erosion scores in ACPA+RF+ patients. Whereas
ACPA+RF +MRI− patients did not have higher erosion
scores than the reference group, ACPA+RF +MRI+ pa-
tients did have higher erosion scores than the ACPA−RF
−MRI− patients (median 2.5 versus 1.0; p < 0.0001). The
erosion score of the ACPA+RF +MRI+ patients was also
higher than that of the ACPA+RF +MRI− patients (median
2.5 versus 1.0; p = 0.039). Together these data showed that
the presence of ACPA and/or RF is only associated with
higher erosion scores if concomitant inflammation is
present.
Discussion
This study evaluated associations between ACPA, RF,
(local) subclinical joint inflammation and erosions in
patients with arthralgia at risk of RA. Presence of ACPA
alone, without inflammation, was not associated with
higher erosion scores, in contrast to the combined pres-
ence of ACPA and inflammation. Mediation analyses
revealed that local inflammation was intermediary in the
causal path to erosions. These results indicate that joint
inflammation has a role in the development of erosions in
ACPA-positive individuals, and suggest that findings in
vitro or mouse models on the independent effect of
ACPAs on erosions are in contrast to findings in humans.
Furthermore, the combination of ACPA and RF, rather
than presence of ACPA alone, was associated with
erosions in patients with arthralgia. These results align
with those obtained in patients with early rheumatoid
arthritis [8, 9] and fuel the hypothesis that ACPAs alone
are not the main and/or single pathogenic factor
contributing to joint erosions. Although one can speculate
how - or if - ACPAs contribute to joint erosions together
with inflammation, results from association studies do not
allow conclusions on biological mechanisms.
Our results suggest that in addition to ACPA, local
joint inflammation is required for more severe erosive
disease. Based on the mediation analysis we cannot
definitely differentiate between full or partial mediation;
the significance for ACPA from step 1 was lost in step 3
Fig. 3 Median erosion scores in patients with Clinically Suspect Arthralgia with triple stratification for anti-citrullinated protein antibodies (ACPA),
rheumatoid factor (RF) and local joint inflammation. Median erosion scores are shown with the upper limit of the interquartile range (75th percentile):
*p < 0.01 compared to the ACPA−RF− magnetic resonance imaging (MRI)−group; **p < 0.01 as compared to the ACPA–RF–MRI– group; NS, non-
significant as compared to the ACPA–RF–MRI– group. The following comparisons were made: ACPA−RF−MRI− patients (median erosion score 1.0) vs.
ACPA+RF−MRI− (median 1.0; p = 0.85), ACPA−RF−MRI− vs. ACPA−RF +MRI− (median 0.5; p = 0.35) and ACPA−RF−MRI− vs. ACPA+RF +MRI− (median
1.0; p = 0.65). ACPA+RF +MRI− patients (median 1.0) vs ACPA−RF +MRI− patients (median 0.5; p = 0.91). Next, ACPA−RF−MRI− patients were compared
to ACPA+RF−MRI+ (median 2.0; p = 0.033) and ACPA−RF +MRI+ patients (median 2.25; p = 0.001). Finally, ACPA+RF +MRI+ patients were compared to
ACPA−RF−MRI− patients (median 2.5 versus 1.0; p < 0.0001) and ACPA+RF +MRI− patients (median 2.5 versus 1.0; p = 0.039). The number of patients
in each group was as follows: ACPA−RF−MRI− (n = 214), ACPA+RF−MRI− (n = 4), ACPA−RF +MRI− (n = 26), ACPA−RF−MRI+ (n = 174), ACPA+RF +MRI
−(n = 8), ACPA−RF +MRI+ (n = 24), ACPA+RF−MRI+ (n = 11) and ACPA+RF +MRI+ (n = 46)
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suggesting full mediation. However, as the beta was not
zero, partial mediation cannot be excluded. Nonetheless,
results of the mediation analyses supported the notion
that erosions in ACPA-positive arthralgia rarely occurred
without concomitant inflammation. This finding is in line
with a previous study that showed that increased levels of
CD19+ B cells and CXCL13 were observed in ACPA-
positive RA and were associated with erosive disease [18].
In this study, the use of sensitive high-quality MRI
data allowed us to detect erosions in a population in
which the total burden of erosions is relatively low. In
contrast to the setting of early inflammatory arthritis
where all patients have current or recent joint inflamma-
tion, the arthralgia setting allows comparison of patients
with and without inflammation.
Not all patients considered at risk of RA will develop
arthritis over time, even though ACPA or (subclinical)
inflammation might be present. However, because we
addressed whether ACPA can directly mediate bone loss
with/without concurrent inflammation, the study could
be performed independent of the final clinical diagnosis.
The subgroups obtained after stratification were small
in some cases (especially the ACPA+RF−MRI− subgroup
after triple stratification), which could lead to underpow-
ered analyses and the possibility of not identifying statisti-
cally significant differences. However, all analyses showed
that erosion scores are highest when both ACPA and in-
flammation are present simultaneously, which strengthens
the overall findings. Finally, our study cannot address the
question as to whether the results are different for specific
ACPA reactivity, as the presence of ACPA was evaluated
using the commercially available CCP2 test.
We studied erosions in humans because a direct effect
of ACPA on erosions has been suggested [5]. Although
loss of trabecular bone as observed in mice may be dis-
similar from periarticular-located erosions in humans,
including the underlying mechanisms, our results indi-
cate that ACPAs do not directly contribute to the forma-
tion of bone erosions, one of the hallmarks of RA.
Conclusions
In conclusion, the present data in patients with arthralgia
showed that erosions are associated with the combined
presence of ACPA and RF, rather than with ACPA alone,
and preferentially occur in patients with joint inflammation.
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